A prospective assessing the safety and efficacy outcomes of 177Lu-DOTATATE in patients with Metastatic Pheochromocytoma/Paraganglioma treated with 177Lu-DOTATATE
Latest Information Update: 22 Jun 2020
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 22 Jun 2020 New trial record